Quantum BioPharma Net Worth
Quantum BioPharma Net Worth Breakdown | QNTM |
Quantum BioPharma Net Worth Analysis
Quantum BioPharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Quantum BioPharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Quantum BioPharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Quantum BioPharma's net worth analysis. One common approach is to calculate Quantum BioPharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Quantum BioPharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Quantum BioPharma's net worth. This approach calculates the present value of Quantum BioPharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Quantum BioPharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Quantum BioPharma's net worth. This involves comparing Quantum BioPharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Quantum BioPharma's net worth relative to its peers.
To determine if Quantum BioPharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Quantum BioPharma's net worth research are outlined below:
| Quantum BioPharma generated a negative expected return over the last 90 days | |
| Quantum BioPharma has high historical volatility and very poor performance | |
| Quantum BioPharma has a very high chance of going through financial distress in the upcoming years | |
| Quantum BioPharma was previously known as HUGE Old and was traded on NASDAQ Exchange under the symbol HUGE. | |
| Net Loss for the year was (17.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Quantum BioPharma generates negative cash flow from operations | |
| Quantum BioPharma has a very weak financial position based on the latest SEC disclosures | |
| About 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Quantum BioPharma Advances Legal Actions Against Former CEO - TipRanks |
Follow Quantum BioPharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.17 M.Evaluate Quantum BioPharma's management efficiency
Quantum BioPharma has return on total asset (ROA) of (0.3612) % which means that it has lost $0.3612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6389) %, meaning that it created substantial loss on money invested by shareholders. Quantum BioPharma's management efficiency ratios could be used to measure how well Quantum BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of January 2025, Intangible Assets is likely to grow to about 9.4 M, while Total Assets are likely to drop about 14.9 M.Understanding the operational decisions made by Quantum BioPharma management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Quantum BioPharma time-series forecasting models is one of many Quantum BioPharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Quantum BioPharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Quantum BioPharma Earnings per Share Projection vs Actual
Quantum BioPharma Corporate Management
| Kevin Cassidy | Vice QualityLucid | Profile | |
| Donal CPA | Chief Officer | Profile | |
| Jason Sawyer | Head Acquisitions | Profile | |
| Maryann Adesso | Corporate Secretary | Profile | |
| Nathan CPA | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Quantum BioPharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Quantum Stock, please use our How to Invest in Quantum BioPharma guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Quantum BioPharma. If investors know Quantum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Quantum BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Quantum BioPharma is measured differently than its book value, which is the value of Quantum that is recorded on the company's balance sheet. Investors also form their own opinion of Quantum BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Quantum BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Quantum BioPharma's market value can be influenced by many factors that don't directly affect Quantum BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Quantum BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Quantum BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Quantum BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.